Eraxis
(Anidulafungin)ApprovedSmall molecule
Anidulafungin is used to treat serious fungal infections, particularly in the bloodstream and other parts of the body. It works by stopping the growth of certain types of fungi that can cause life-threatening infections, especially in hospitalized patients with weakened immune systems.[2] Eraxis is currently approved and in use across 14 indications[4].[1]
Eraxis is one of 305 small molecule programs targeting Neutropenia. It is currently in Approved.
14
Indications
23
Total Trials
0
Active Trials
304
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Eraxis
VVicuron Pharmaceuticals
Approved
Intron a
SanofiPhase 3
Dalalone
CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 3
Caspofungin Acetate
Merck & Co.Phase 3
Experimental
BiogenPhase 3
ALL-Trans Retinoic Acid (ATRA)
IncytePhase 3
AG-120
Institut de Recherches Internationales ServierPhase 3
Valspodar
EEastern Cooperative Oncology Group
Phase 3
Salvage Chemotherapy
Daiichi SankyoPhase 3
Homoharringtonine
Ascentage Pharma Group Inc.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Aspergillosis4 trials
Candidiasis4 trials
Show 1 more trial
Candidemia2 trials
Intravenous Administration1 trial
10 more indications
Critically Ill Patients1 trial
Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment
Terminated·—·Phase 2·NCT00934934·61 enrolled
Immunocompromised1 trial
Liver Disease1 trial
Infection1 trial
Antimicrobial PK in Infants With Suspected or Confirmed Infection
Completed·—··NCT00491426·450 enrolled
Liver Transplant1 trial
Transplant Recipient1 trial
Regulatory
FDA Approval Timeline[5]
Feb 17, 2006
ERAXIS
NDA NDA021632
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Eraxis drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Anidulafungin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- 1,3-Beta-Glucan Synthase Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- VVicuron Pharmaceuticals